Literature DB >> 26149216

ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.

Pei Zhang1, Shuwen Yu2, Hongyu Li3, Chuanyong Liu1, Juan Li1, Wenli Lin1, Aiqin Gao1, Linlin Wang1, Wei Gao4, Yuping Sun5.   

Abstract

Immunoglobulin-like transcript (ILT) 4 is critical for the inhibitory function of certain immune cells. We previously demonstrated that ILT4 is over-expressed in human non-small cell lung cancer (NSCLC) cells and is involved in tumour evasion via an unknown mechanism. In this report, we demonstrate that ILT4 increases the expression of the co-inhibitory molecule B7-H3 through PI3K/AKT/mTOR signalling. In primary human NSCLC tissues, a significant positive relationship is observed between ILT4 and B7-H3 expression. ILT4/B7-H3 co-expression is significantly associated with a reduction in T infiltrating lymphoid cells and lower overall survival. In summary, ILT4 increases B7-H3 expression and ILT4/B7-H3 co-expression may be involved in NSCLC progression.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  B7-H3; ILT4; Non-small cell lung cancer; PI3K/AKT/mTOR signalling

Mesh:

Substances:

Year:  2015        PMID: 26149216     DOI: 10.1016/j.febslet.2015.06.037

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  22 in total

1.  Allicin inhibits the invasion of lung adenocarcinoma cells by altering tissue inhibitor of metalloproteinase/matrix metalloproteinase balance via reducing the activity of phosphoinositide 3-kinase/AKT signaling.

Authors:  Ling Huang; Yuanhong Song; Jianping Lian; Zhiwei Wang
Journal:  Oncol Lett       Date:  2017-05-05       Impact factor: 2.967

2.  Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Authors:  Zijun Y Xu-Monette; Ling Li; John C Byrd; Kausar J Jabbar; Ganiraju C Manyam; Charlotte Maria de Winde; Michiel van den Brand; Alexandar Tzankov; Carlo Visco; Jing Wang; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Ben M Parsons; Jane N Winter; Michael Wang; Frederick B Hagemeister; Miguel A Piris; J Han van Krieken; L Jeffrey Medeiros; Yong Li; Annemiek B van Spriel; Ken H Young
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

3.  Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4.

Authors:  Nathalie Rouas-Freiss; Joel LeMaoult; Jérôme Verine; Diana Tronik-Le Roux; Stéphane Culine; Christophe Hennequin; François Desgrandchamps; Edgardo D Carosella
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

4.  Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells.

Authors:  Shasha Zhao; Yuelong Wang; Nian Yang; Min Mu; Zhiguo Wu; Hexian Li; Xin Tang; Kunhong Zhong; Zongliang Zhang; Cheng Huang; Ting Cao; Meijun Zheng; Guoqing Wang; Chunlai Nie; Hui Yang; Gang Guo; Liangxue Zhou; Xi Zheng; Aiping Tong
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

5.  Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.

Authors:  Elodie Picarda; Kim C Ohaegbulam; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2016-05-20       Impact factor: 12.531

6.  Co-expression of ILT4/HLA-G in human non-small cell lung cancer correlates with poor prognosis and ILT4-HLA-G interaction activates ERK signaling.

Authors:  Yanwen Zhang; Jianqiang Zhao; Lijun Qiu; Pei Zhang; Juan Li; Dong Yang; Xiaojuan Wei; Yali Han; Siyue Nie; Yuping Sun
Journal:  Tumour Biol       Date:  2016-03-03

7.  B7-H3 targeted antibody-based immunotherapy of malignant diseases.

Authors:  Theodoros Michelakos; Filippos Kontos; Omar Barakat; Luke Maggs; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Expert Opin Biol Ther       Date:  2020-12-21       Impact factor: 4.388

Review 8.  B7-H3: An Attractive Target for Antibody-based Immunotherapy.

Authors:  Filippos Kontos; Theodoros Michelakos; Tomohiro Kurokawa; Ananthan Sadagopan; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Clin Cancer Res       Date:  2020-10-13       Impact factor: 13.801

Review 9.  Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors.

Authors:  Xunlei Kang; Jaehyup Kim; Mi Deng; Samuel John; Heyu Chen; Guojin Wu; Hiep Phan; Cheng Cheng Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

10.  Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.

Authors:  Caroline E Nunes-Xavier; Karine Flem Karlsen; Christina Tekle; Cathrine Pedersen; Tove Øyjord; Vesa Hongisto; Jahn M Nesland; Ming Tan; Kristine Kleivi Sahlberg; Øystein Fodstad
Journal:  Oncotarget       Date:  2016-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.